Auris Medical Announces AAO-HNSF Annual Meeting Activities
13 September 2016 - 10:13PM
- Presentation of safety data from KeyzilenTM program and
symposium on tinnitus pharmacotherapy set for September 18 and
19
ZUG, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Auris
Medical Holding AG (NASDAQ:EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology, today announced that safety data
from the KeyzilenTM (AM-101) program will be presented at the 2016
Annual Meeting & OTO EXPOSM of the American Academy of
Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). In
addition, the company will host a corporate symposium featuring
experts in the field of tinnitus research.[1]
Hinrich Staecker, MD, PhD, Professor of Otolaryngology at the
University of Kansas Medical Center, will deliver an oral
presentation titled "Safety of Repeated Intratympanic AM-101 in
Acute Inner Ear Tinnitus" on September 18, 2016, at 11:40 am PDT at
the San Diego Convention Center in Room 31A.
On September 19, 2016, at 6 pm PDT, Auris Medical will host a
corporate symposium titled "Advancing Pharmacotherapy for
Tinnitus." The event will include presentations by Marlies Knipper,
PhD, on the development of peripheral and central tinnitus;
Lawrence R. Lustig, MD, on the history of intratympanic drug
therapy; James A. Henry, PhD, on the clinical use of the Tinnitus
Functional Index; and Hinrich Staecker, MD, PhD, on the clinical
development of the NMDA receptor antagonist AM-101. The symposium
will take place at the Hilton Bayfront Hotel in San Diego, and a
webcast will be available in the Investor Relations section of the
Auris Medical website at www.aurismedical.com following the
event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in otolaryngology. The Company is currently
focusing on the Phase 3 development of treatments for acute inner
ear tinnitus (KeyzilenTM; AM-101) and for acute inner ear hearing
loss (AM-111) by way of intratympanic administration with
biocompatible gel formulations. In addition, Auris Medical is
pursuing early-stage research and development projects. The Company
was founded in 2003 and is headquartered in Zug, Switzerland. The
shares of the parent company Auris Medical Holding AG trade on the
NASDAQ Global Market under the symbol "EARS."
[1] This event is not part of the official AAO-HNSF 2016 Annual
Meeting & OTO EXPOSM.
Forward-looking Statements
This press release may contain statements that
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements are
statements other than historical fact and may include statements
that address future operating, financial or business performance or
Auris Medical's strategies or expectations. In some cases, you can
identify these statements by forward-looking words such as "may,"
"might," "will," "should," "expects," "plans," "anticipates,"
"believes," "estimates," "predicts," "projects," "potential,"
"outlook" or "continue," and other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the timing and conduct of clinical trials of Auris
Medical's product candidates, the clinical utility of Auris
Medical's product candidates, the timing or likelihood of
regulatory filings and approvals, Auris Medical's intellectual
property position and Auris Medical's financial position, including
the impact of any future acquisitions, dispositions, partnerships,
license transactions or changes to Auris Medical's capital
structure, including future securities offerings. These risks and
uncertainties also include, but are not limited to, those described
under the caption "Risk Factors" in Auris Medical's Annual Report
on Form 20-F and future filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date
they are made, and Auris Medical does not undertake any obligation
to update them in light of new information, future developments or
otherwise, except as may be required under applicable law. All
forward-looking statements are qualified in their entirety by this
cautionary statement.
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Media contact: David Schull, Russo Partners,
1-858-717-2310, david.schull@russopartnersllc.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2024 to May 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From May 2023 to May 2024